ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2116

The Associations of HLA-DR Shared Epitope Alleles and Serum Cytokines Among Postmenopausal Women with Rheumatoid Factor and Anti-Citrullinated Protein Antibody-Positive Rheumatoid Arthritis

Mehret Birru Talabi1, Rachel Mackey2, Larry W. Moreland3, Jan Dorman4, Kevin D. Deane5, Jeremy Sokolove6, V. Michael Holers7, William H. Robinson8, Brian Wallitt9 and Lewis Kuller10, 1Department of Internal Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, 2Department of Epidemiology, University of Pittsburgh, Pittsburgh, PA, 3Division of Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, 4School of Nursing, University of Pittsburgh School of Nursing, Pittsburgh, PA, 5Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, 6Medicine, VA Palo Alto Health Care System and Stanford University, Palo Alto, CA, 7Rheumatology Division, University of Colorado School of Medicine, Aurora, CO, 8Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, 9Washington Hospital Center, Baltimore, MD, 10Epidemiology, University of Pittsburgh, Pittsburgh, PA

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: anti-CCP antibodies, cytokines, human leukocyte antigens (HLA), rheumatoid arthritis (RA) and women's health

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis - Clinical Aspects III: Infections/Risk Factors for Incident Rheumatoid Arthritis/Metrology/Classification/Biomarkers/Predictors of Rheumatolid Arthritis Activity & Severity

Session Type: Abstract Submissions (ACR)

Title: The Associations of HLA-DRβ1 Shared Epitope Alleles and Serum Cytokines Among Postmenopausal Women with Rheumatoid Factor and Anti-Citrullinated Protein Antibody-Positive Rheumatoid Arthritis

Background/Purpose: This study evaluates associations between HLA-DRβ1 associated shared epitope (SE) alleles and cytokines among postmenopausal women with rheumatoid arthritis (RA).  Presence of 1 or 2 versus absence of SE alleles is associated with more erosive RA in a number of studies.  Fewer studies have examined if the number of SE alleles is associated with markers of inflammation. 

Methods: Participants (n=2877) were enrolled in a substudy of the Women’s Health Initiative, and reported RA on questionnaires. Rheumatoid factor (RF), anti-citrullinated protein antibodies (ACPA), HLA- DRβ1 genotyping, and cytokines (IL-1B, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-13, IL-12, IL-17, TNFα, MCP-1, MIF-1, IFN-Y, GCSF) were measured. SEs included QKRAA, KRRAA, RRRAA. Kruskal-Wallis tests were used to evaluate median cytokine concentrations by SE allele frequencies.  

Results: Women included in this analysis (n=591) were RF and ACPA-positive. N=208 had 0 SE alleles, n=288 had 1 SE, and n=95 had 2 SEs.  Several cytokines showed a dose-response increase from 0 to 1 to 2 SEs (underlined in table), with IL-2 and IL-6 showing the most marked differences (p<0.05 for differences between SE categories).

Table 1.  Median (Interquartile Range) Cytokine Levels by Number of Shared Epitopes in ACPA/RF+ Women

 

Shared Epitopes

Cytokines

0 (n=208)

1 (n=288)

2 (n=95)

p-value

 

IL-2

11.3 (4.3-35.1)

12.7 (5.6-41.6)

19.0 (6.4-60.6)

0.047

IL-6

11.8 (6.4-32.6)

15.3 (8.5-35.3)

20.3 (10.1-56.5)

0.003

IFN-Y

68.8 (39.1-171.2)

77.4 (43.8-196.8)

87.7 (48.6-214.6)

0.22

MCP1

20.2 (13.4-33.1)

21.5 (15.1-36.7)

23.6 (13.5-42.6)

0.24

IL-1b

2.2 (1.4-5.0)

2.4 (1.6-6.4)

2.6 (1.7-7.1)

0.18

IL-10

3.0 (2.0-5.3)

3.2 (2.3-5.0)

3.5 (2.4-5.7)

0.32

IL-4

2.3 (1.3-3.7)

2.32 (1.5-3.6)

2.2 (1.5-3.2)

0.80

IL-5

4.0 (2.8-5.9)

4.2 (3.0-6.6)

4.0 (2.9-6.0)

0.46

IL-7

8.4 (6.0-11.5)

8.6 (6.5-12.8)

8.4 (6.1-11.6)

0.47

IL-8

9.6 (7.4-12.8)

10.1 (7.4-13.2)

9.6 (7.3-12.7)

0.50

IL-12

22.2 (12.2-65.5)

23.3 (14.0-53.4)

21.7 (13.5-69.6)

0.82

IL-13

4.0 (2.3-10.5)

4.4 (2.7-10.2)

4.2 (2.6-11.3)

0.46

GCSF

165.8 (112.7-224.2)

175.2 (120.0-235.8)

167.4 (124.8)

0.62

MIP1b

44.2 (33.0-61.5)

47.5 (34.4-65.8)

45.9 (36.1-64.6)

0.40

TNF-α

35.3 (20.1-79.6)

38.8 (23.6-88.5)

38.5 (24.7-125.0)

0.22

IL-17

4.6 (0-11.6)

4.6 (0-13.3)

3.1 (0-8.7)

0.23

 

Conclusion: ACPA/RF+ women with 2 SE alleles had higher IL-2 and IL-6 levels than did women with fewer SE alleles. Studies indicate that Il-6 induces IL-2 proliferation, which in turn induces cytotoxic T cell differentiation.  A pro-inflammatory milieu may explain why higher numbers of SE alleles are associated with more destructive arthropathy. IL-6 may be a particularly important therapeutic target among these women.  Future work should examine whether these associations differ with use of disease-modifying anti-rheumatic drugs.

 


Disclosure:

M. Birru Talabi,
None;

R. Mackey,
None;

L. W. Moreland,
None;

J. Dorman,
None;

K. D. Deane,
None;

J. Sokolove,
None;

V. M. Holers,
None;

W. H. Robinson,
None;

B. Wallitt,
None;

L. Kuller,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-associations-of-hla-dr-shared-epitope-alleles-and-serum-cytokines-among-postmenopausal-women-with-rheumatoid-factor-and-anti-citrullinated-protein-antibody-positive-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology